The Genomic Health Inc. (GHDX) Receives $30.88 Average PT from Brokerages

The Genomic Health Inc. (GHDX) Receives $30.88 Average PT from Brokerages

Genomic Health Inc. (NASDAQ:GHDX) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $30.88.

A number of brokerages have weighed in on GHDX. Canaccord Genuity reaffirmed a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a research report on Friday, August 5th. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Tuesday, October 4th. Bank of America Corp. set a $28.00 price objective on Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd. Jefferies Group boosted their price objective on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Finally, Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st.

Genomic Health (NASDAQ:GHDX) opened at 29.30 on Wednesday. The firm’s market cap is $977.04 million. The stock has a 50 day moving average price of $28.36 and a 200 day moving average price of $27.34. Genomic Health has a 12 month low of $20.05 and a 12 month high of $35.79.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The company earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. The business’s quarterly revenue was up 16.1% compared to the same quarter last year. On average, equities analysts expect that Genomic Health will post ($0.47) earnings per share for the current fiscal year.

In other news, insider James J. Vaughn sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $28.74, for a total value of $86,220.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 19th. The shares were sold at an average price of $27.42, for a total value of $137,100.00. Following the completion of the sale, the insider now owns 332,207 shares in the company, valued at $9,109,115.94. The disclosure for this sale can be found here. Corporate insiders own 47.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. raised its stake in Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock valued at $278,000 after buying an additional 334 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock valued at $309,000 after buying an additional 351 shares during the last quarter. Kimelman & Baird LLC increased its position in shares of Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock valued at $543,000 after buying an additional 500 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Genomic Health by 2.2% in the second quarter. ProShare Advisors LLC now owns 26,858 shares of the company’s stock valued at $695,000 after buying an additional 591 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Genomic Health by 2.3% in the second quarter. Swiss National Bank now owns 31,200 shares of the company’s stock valued at $808,000 after buying an additional 700 shares during the last quarter. Institutional investors own 88.92% of the company’s stock.

Related posts

Leave a Comment